CoChat

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development

Open access

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.ade5111

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. ENT4 is overexpressed, while ADK is suppressed in human HCC. (A) Schematic representation of pathways involved in adenosine metabolism. (B) ADK mRNA expression in paired HCC and NT (nontumorous) tissues from (left) University of Hong Kong-Queen Mary Hospital (HKU-QMH) patients and (right) The Cancer Genome Atlas (TCGA) database. (C) Kaplan-Meier curves showing the association of ADK mRNA expression with (left) overall and (right) disease-free survival in patients with HCC from TCGA database. (D) ENT4 mRNA expression in paired HCC and NT tissues from (left) HKU-QMH patients and (right) TCGA database. (E) Kaplan-Meier curves showing the association of ENT4 mRNA expression with (left) overall and (right) disease-free survival in patients with HCC from TCGA database. *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus NT. (B) and (D) Student’s t test. (C) and (E) Kaplan-Meier followed by log-rank test. RSEM, RNA sequencing expression estimation by expectation maximization.
Fig. 1. ENT4 is overexpressed, while ADK is suppressed in human HCC. (A) Schematic representation of pathways involved in adenosine metabolism. (B) ADK mRNA expression in paired HCC and NT (nontumorous) tissues from (left) University of Hong Kong-Queen Mary Hospital (HKU-QMH) patients and (right) The Cancer Genome Atlas (TCGA) database. (C) Kaplan-Meier curves showing the association of ADK mRNA expression with (left) overall and (right) disease-free survival in patients with HCC from TCGA database. (D) ENT4 mRNA expression in paired HCC and NT tissues from (left) HKU-QMH patients and (right) TCGA database. (E) Kaplan-Meier curves showing the association of ENT4 mRNA expression with (left) overall and (right) disease-free survival in patients with HCC from TCGA database. *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus NT. (B) and (D) Student’s t test. (C) and (E) Kaplan-Meier followed by log-rank test. RSEM, RNA sequencing expression estimation by expectation maximization.CC BY-NC · PubMed Central
Fig. 2. ADK and ENT4 are regulated by hypoxia via HIF. (A) ADK mRNA expression in human HCC cell lines including MHCC97L, Hep3B, CLC6, and CLC11 exposed to 20 and 1% O2 for 24 hours. (B) ADK mRNA expression in MHCC97L-shHIF1β cells compared to NTC (nontargeting control) exposed to 20 and 1% O2 for 24 hours. (C) MXI1 mRNA expression in MHCC97L-shHIF-1β cells compared to NTC exposed to 20 and 1% O2 for 24 hours. (D) Left: Schematic representation of competition of MYC and MXI1 for E-box element binding under hypoxia and the binding site at ADK promoter region. Right: ChIP assay on MHCC97L cells exposed to 20 and 1% O2 using MXI1, MYC, and immunoglobulin G (IgG) antibodies. (E) ENT4 mRNA expression in human HCC cell lines including MHCC97L, Hep3B, CLC6, and CLC11 exposed to 20 and 1% O2 for 24 hours. (F) ENT4 mRNA expression in MHCC97L-shHIF-1β cells compared to NTC exposed to 20 and 1% O2 for 24 hours. (G) Left: Putative HRE at the promoter region of ENT4. Right: ChIP assay in MHCC97L cells exposed to 20 and 1% O2 using HIF-1β and IgG antibodies. (H) Relative luciferase activity in MHCC97L cells transfected with luciferase plasmids containing WT HRE or MUT HRE. (A) to (C), (E), and (F) mRNA expression was determined by quantitative real-time polymerase chain reaction (qRT-PCR), and values were normalized to 20% O2 or 20% O2 NTC. (D) and (G) Fold of enrichment was normalized to the corresponding IgG controls. (H) Relative luciferase activity was normalized to 20% O2 WT or 20% O2 MUT, respectively. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 20% O2, 20% O2 NTC, IgG, 20% O2 WT, or 20% O2 MUT as indicated. Student’s t test.
Fig. 2. ADK and ENT4 are regulated by hypoxia via HIF. (A) ADK mRNA expression in human HCC cell lines including MHCC97L, Hep3B, CLC6, and CLC11 exposed to 20 and 1% O2 for 24 hours. (B) ADK mRNA expression in MHCC97L-shHIF1β cells compared to NTC (nontargeting control) exposed to 20 and 1% O2 for 24 hours. (C) MXI1 mRNA expression in MHCC97L-shHIF-1β cells compared to NTC exposed to 20 and 1% O2 for 24 hours. (D) Left: Schematic representation of competition of MYC and MXI1 for E-box element binding under hypoxia and the binding site at ADK promoter region. Right: ChIP assay on MHCC97L cells exposed to 20 and 1% O2 using MXI1, MYC, and immunoglobulin G (IgG) antibodies. (E) ENT4 mRNA expression in human HCC cell lines including MHCC97L, Hep3B, CLC6, and CLC11 exposed to 20 and 1% O2 for 24 hours. (F) ENT4 mRNA expression in MHCC97L-shHIF-1β cells compared to NTC exposed to 20 and 1% O2 for 24 hours. (G) Left: Putative HRE at the promoter region of ENT4. Right: ChIP assay in MHCC97L cells exposed to 20 and 1% O2 using HIF-1β and IgG antibodies. (H) Relative luciferase activity in MHCC97L cells transfected with luciferase plasmids containing WT HRE or MUT HRE. (A) to (C), (E), and (F) mRNA expression was determined by quantitative real-time polymerase chain reaction (qRT-PCR), and values were normalized to 20% O2 or 20% O2 NTC. (D) and (G) Fold of enrichment was normalized to the corresponding IgG controls. (H) Relative luciferase activity was normalized to 20% O2 WT or 20% O2 MUT, respectively. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 20% O2, 20% O2 NTC, IgG, 20% O2 WT, or 20% O2 MUT as indicated. Student’s t test.CC BY-NC · PubMed Central
Fig. 3. Adenosine promotes Treg differentiation and cell death while suppressing T cell proliferation and functions. (A) CellTrace Violet (CTV) T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA (adenosine stable analog) for 3 days with IL-2. (B) Percentages of (left) IFN-γ+ and (right) granzyme B+ CD8+ T cells treated with indicated doses of NECA for 3 days with IL-2. (C) Percentage of cell death of (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA for 3 days with IL-2. (D) Splenic T cells were cultured with 100 μM NECA in the presence of vehicle [dimethyl sulfoxide (DMSO)], 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 3 days with IL-2. The percentage of Tregs (CD4+ CD25+FOXP3+) was determined by flow cytometry. (E to H) Bulk RNA sequencing was performed on NECA-treated T cells compared to vehicle (DMSO). (E) to (G) GSEA showed the enrichment of selected gene sets in NECA-treated T cells. (H) Fold change of selected genes as compared to vehicle. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test. ns, not significant.
Fig. 3. Adenosine promotes Treg differentiation and cell death while suppressing T cell proliferation and functions. (A) CellTrace Violet (CTV) T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA (adenosine stable analog) for 3 days with IL-2. (B) Percentages of (left) IFN-γ+ and (right) granzyme B+ CD8+ T cells treated with indicated doses of NECA for 3 days with IL-2. (C) Percentage of cell death of (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA for 3 days with IL-2. (D) Splenic T cells were cultured with 100 μM NECA in the presence of vehicle [dimethyl sulfoxide (DMSO)], 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 3 days with IL-2. The percentage of Tregs (CD4+ CD25+FOXP3+) was determined by flow cytometry. (E to H) Bulk RNA sequencing was performed on NECA-treated T cells compared to vehicle (DMSO). (E) to (G) GSEA showed the enrichment of selected gene sets in NECA-treated T cells. (H) Fold change of selected genes as compared to vehicle. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test. ns, not significant.CC BY-NC · PubMed Central
Fig. 4. Adenosine skews myeloid cells to immunosuppressive phenotypes. (A and B) Bone marrow progenitor cells were cultured with 10 μM NECA in the presence of vehicle (DMSO), 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 5 days with IL-4 and GM-CSF. The percentages of (A) MDSC and (B) DC were determined by flow cytometry. (C and D) Bulk RNA sequencing was performed on NECA-treated bone marrow progenitor cells. (C) GO term enrichment analysis revealed the top five GO terms most enriched in NECA-treated bone marrow cells as compared to vehicle control. (D) Dot plot showed the fold change of a panel of chemokines as compared to vehicle. (E) Percentages of (left) MHCII+ and (right) CD206+ bone marrow–derived macrophages treated with indicated doses of NECA for 2 days with M-CSF. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test.
Fig. 4. Adenosine skews myeloid cells to immunosuppressive phenotypes. (A and B) Bone marrow progenitor cells were cultured with 10 μM NECA in the presence of vehicle (DMSO), 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 5 days with IL-4 and GM-CSF. The percentages of (A) MDSC and (B) DC were determined by flow cytometry. (C and D) Bulk RNA sequencing was performed on NECA-treated bone marrow progenitor cells. (C) GO term enrichment analysis revealed the top five GO terms most enriched in NECA-treated bone marrow cells as compared to vehicle control. (D) Dot plot showed the fold change of a panel of chemokines as compared to vehicle. (E) Percentages of (left) MHCII+ and (right) CD206+ bone marrow–derived macrophages treated with indicated doses of NECA for 2 days with M-CSF. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test.CC BY-NC · PubMed Central
Fig. 5. ADK deficiency and ENT4 overexpression (OE) elevate extracellular adenosine level and suppress T cell proliferation. (A and B) Conditioned media of (A) Hepa1–6 Cas9–AdkKO cells and (B) Hepa1–6–Ent4OE cells exposed to 20 and 1% O2 for 48 hours were harvested, and extracellular adenosine levels were determined by MS. (C and D) CTV T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells cocultured with (C) Hepa1–6 Cas9–AdkKO cells or (D) Hepa1–6–Ent4OE cells for 3 days with IL-2. (A) and (B) Relative adenosine level was normalized to 20% O2 empty vector (EV). Error bars indicate means ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 versus EV or 20% O2 EV. Student’s t test.
Fig. 5. ADK deficiency and ENT4 overexpression (OE) elevate extracellular adenosine level and suppress T cell proliferation. (A and B) Conditioned media of (A) Hepa1–6 Cas9–AdkKO cells and (B) Hepa1–6–Ent4OE cells exposed to 20 and 1% O2 for 48 hours were harvested, and extracellular adenosine levels were determined by MS. (C and D) CTV T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells cocultured with (C) Hepa1–6 Cas9–AdkKO cells or (D) Hepa1–6–Ent4OE cells for 3 days with IL-2. (A) and (B) Relative adenosine level was normalized to 20% O2 empty vector (EV). Error bars indicate means ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 versus EV or 20% O2 EV. Student’s t test.CC BY-NC · PubMed Central
Fig. 6. ADK deficiency promotes HCC progression and creates an immunosuppressive TME. (A) In vivo HCC tumors were induced via HDTVi of plasmids carrying Trp53KO/c-MycOE (EV) or Trp53KOAdkKO/c-MycOE (-43 and -101) in C57BL/6N mice. (Left) Liver mass and (right) representative picture of harvested livers with tumors. (B to F) Flow cytometry analysis was performed to determine tumor infiltration of immune cells. (B) Left: Quantification of CD8+ T cells. Right: Representative contour plots. (C) Percentage of effector T cells (CD8+CD44+CD62L−) expressing multiple exhaustion markers. (D) Left: Quantification of CD4+ T cells. Right: Representative contour plots. (E) Quantification of (top) CD8+ and (bottom) CD4+ T cells in tumor by immunohistochemistry staining. (F) Left: Quantification of DCs. Right: Representative contour plots. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus empty vector (EV). Student’s t test. Scale bar, 1 cm.
Fig. 6. ADK deficiency promotes HCC progression and creates an immunosuppressive TME. (A) In vivo HCC tumors were induced via HDTVi of plasmids carrying Trp53KO/c-MycOE (EV) or Trp53KOAdkKO/c-MycOE (-43 and -101) in C57BL/6N mice. (Left) Liver mass and (right) representative picture of harvested livers with tumors. (B to F) Flow cytometry analysis was performed to determine tumor infiltration of immune cells. (B) Left: Quantification of CD8+ T cells. Right: Representative contour plots. (C) Percentage of effector T cells (CD8+CD44+CD62L−) expressing multiple exhaustion markers. (D) Left: Quantification of CD4+ T cells. Right: Representative contour plots. (E) Quantification of (top) CD8+ and (bottom) CD4+ T cells in tumor by immunohistochemistry staining. (F) Left: Quantification of DCs. Right: Representative contour plots. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus empty vector (EV). Student’s t test. Scale bar, 1 cm.CC BY-NC · PubMed Central
Fig. 7. Adenosine receptors blockade synergizes with anti–PD-1 treatment. (A) In vivo HCC tumors were induced via HDTVi of plasmids carrying Trp53KO/c-MycOE in C57BL/6N mice. (Left) Survival plot and (right) body weight of HCC-bearing mice treated with vehicle, adenosine receptor antagonists, anti–PD-1 monoclonal antibodies, or the combination of both. (B) Representative pictures (left) and quantification (right) of CD8+ T cells in tumor by immunohistochemistry staining. (C) Percentage of effector T cells (CD8+CD44+CD62L−) expressing IFN-γ. (D) Quantification of DCs in tumor by flow cytometry. (E) Schematic summary of the role of HIF in promoting intracellular adenosine efflux and mediating immunosuppressive TME. Error bars indicate means ± SD. **P < 0.01 versus vehicle. (A) Kaplan-Meier followed by log-rank test. (B) Student’s t test. Original, 20× magnification (scale bars, 100 μm); Inset, 40× magnification (scale bars, 50 μm).
Fig. 7. Adenosine receptors blockade synergizes with anti–PD-1 treatment. (A) In vivo HCC tumors were induced via HDTVi of plasmids carrying Trp53KO/c-MycOE in C57BL/6N mice. (Left) Survival plot and (right) body weight of HCC-bearing mice treated with vehicle, adenosine receptor antagonists, anti–PD-1 monoclonal antibodies, or the combination of both. (B) Representative pictures (left) and quantification (right) of CD8+ T cells in tumor by immunohistochemistry staining. (C) Percentage of effector T cells (CD8+CD44+CD62L−) expressing IFN-γ. (D) Quantification of DCs in tumor by flow cytometry. (E) Schematic summary of the role of HIF in promoting intracellular adenosine efflux and mediating immunosuppressive TME. Error bars indicate means ± SD. **P < 0.01 versus vehicle. (A) Kaplan-Meier followed by log-rank test. (B) Student’s t test. Original, 20× magnification (scale bars, 100 μm); Inset, 40× magnification (scale bars, 50 μm).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

Metadata

Authors
Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., Zhang, M. S., Bao, M. H.-R., Wong, B. P.-Y., Chan, C. Y.-K., Liu, C. X., Sit, G. F.-W., Ooi, Z. Y., Deng, H., Tse, A. P.-W., Ng, I. O.-L., & Wong, C. C.-L.
Affiliations
  • University of Hong Kong (HK)
  • Sun Yat-sen University (CN)
Corresponding author
Wong, Carmen Chak-Lui
Venue
Science Advances
Published
2023-05-05
Volume
9
Issue
18
Pages
eade5111-eade5111
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4372332351
Cited by
65
References
61
Citations by year
2026: 20 · 2025: 24 · 2024: 20 · 2023: 1
FWCI
12.15
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82022077)
  • University of Hong Kong
  • Directorate for Biological Sciences
  • Cornell Center for Materials Research
  • Young Scientists Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
HIF-1, hepatocellular carcinoma, adenosine metabolism, adenosine kinase, MXI1, immunosuppressive tumor microenvironment, adenosine receptor antagonists, anti-PD-1 combination therapy, immune checkpoint inhibitors, tumor hypoxia
MeSH terms
Adenosine, Animals, Hypoxia, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Knockout, Cell Line, Tumor, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.